Dupuytren Contracture - Pipeline Review, H2 2017
|出版商||Global Markets Direct||商品編碼||484629|
|出版日期||內容資訊||英文 31 Pages
|掌腱膜攣縮症:開發中產品分析 Dupuytren Contracture - Pipeline Review, H2 2017|
|出版日期: 2017年09月12日||內容資訊: 英文 31 Pages||
掌腱膜攣縮症(Dupuytren′s Contracture)是一種侵犯掌腱膜，並延伸至手指筋膜，最終導致掌指及指間關節攣縮的緩慢進行性發展的疾病。它會在手掌皮膚下面形成局部的瘢痕組織。瘢痕積聚在通常覆蓋拉扯手指抓握的肌腱組織中。隨著掌腱膜攣縮症惡化，更多的膜變厚和縮短。皮膚在該區域最終會燮成皮膚窪陷發生皺紋。掌腱膜攣縮症的進展速度從輕微皮膚皺褶多年到手指的快速攣縮（固定彎曲位置）而有所不同。受到它的影響手指可能錯位到完全無法伸直 。因此還可能導致喪失正常抓握力。掌腱膜攣縮症少有疼痛，除非受影響的手指被無意的過度伸展。掌腱膜攣縮症纖維增生性障礙。該疾病會導致手指攣縮，並可能導致顯著的畸形和殘疾。造成這種疾病的因素包括種族，遺傳傾向，性別和年齡。風險因素（環境）包括飲酒，吸煙，創傷，癲癇和糖尿病。如果手指以十分大的角度扭曲，在治療後一般會接受讓手指可伸直的手術。
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dupuytren Contracture - Pipeline Review, H2 2017, provides an overview of the Dupuytren Contracture (Musculoskeletal Disorders) pipeline landscape.
Dupuytren contracture is a hand deformity that usually develops slowly, over decades. Dupuytren contracture affects the connective tissue under the skin of the palm. It is a localized formation of scar tissue beneath the skin of the palm of the hand. The scarring accumulates in a tissue that normally covers the tendons that pull the fingers to grip. As Dupuytren contracture progresses, more of the fascia becomes thickened and shortened. Dimpling and puckering of the skin over the area eventually occurs. Dupuytren contracture varies in its rate of progression from minor skin puckering for many years to rapid contracture (fixed flexed position) of fingers. Dupuytren contracture can lead to an inability to fully extend the affected finger from the flexed position. This can result in a loss of normal grasping. Dupuytren contracture is seldom associated with much, if any, pain unless the affected fingers are inadvertently forcefully hyperextended. Dupuytren contracture is a fibroproliferative disorder. It involves the tissue beneath the palm of the hand that leads to finger contracture and may result in significant deformity and disability. Factors contributing to the disease include ethnicity, genetic predisposition, sex and age. Risk factors (environmental) include alcohol consumption, smoking, trauma, epilepsy and diabetes. Dupuytren contracture is usually treated by an operation to straighten the fingers followed by therapy if the angle that the fingers are bent at is large enough. Surgical treatment requires extensive postoperative therapy and there are chances that symptoms often re-occur. The molecular pathophysiology of Dupuytren contracture is complex. Extensive exploration of the molecular basis of Dupuytren contracture has led to the development of new treatment modalities such as by Clostridium histolyticum collagenase injection. There still remains a long way in the development of more promising therapies for Dupuytren contracture.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dupuytren Contracture - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dupuytren Contracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dupuytren Contracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dupuytren Contracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Dupuytren Contracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.